Despite its enormous global burden, osteoarthritis has no licensed disease-modifying treatments, and available analgesics have moderate efficacy and substantial side-effects.1 The success of ...

IN FACT, THE NEW BRIDGE IS ACTUALLY GOING TO BE TWO BRIDGES BUILT SIDE BY SIDE, RIGHT ON THE OTHER SIDE, JUST TO THE WEST ...

Successfully completed Initial Public Offering (IPO) in February 2026, raising $172.5 million and listing on Nasdaq.Reported positive topline 12-month data from Phase 1/2 trial of the Bimatoprost Drug ...

Qatar is accustomed to instability in its backyard disrupting delicate supply chains and eating into its bottom line. During ...

Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer P ...

Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP)The study size was expanded to 183 participants due to patient and ...

Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple ...

U.S. grid operator PJM ​has told Constellation Energy that the former Three Mile ‌Island nuclear power plant in Pennsylvania ...

A team of researchers led by the University of Pittsburgh demonstrated a programmable superconducting diode at the ...

WhiteFiber, Inc. (Nasdaq: WYFI) ("WhiteFiber" or the "Company"), a leading provider of AI infrastructure and high-performance computing solutions, today announced financial results for the fourth ...

The U.S. Army Human Resources Command is conducting a large-scale mobilization exercise, or MOBEX, to test the unit’s ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today reported its business update and consolidated financial results for the year ending December 31, 2025. The ...